Abstracts tagged "T-Regulatory Cells"

Abstract Number: 2713 • 2013 ACR/ARHP Annual Meeting
IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive Germinal Center Development In Autoimmune BXD2 Mice
Yanna Ding¹, Hui-Chen Hsu^2,3, Jun Li⁴, PingAr Yang⁴, Qi Wu⁴, Allan J. Zajac⁵ and John D. Mountz^3,6, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Birmingham VA Medical Center, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Microbiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Follicular T helper (Tfh) cells have been correlated with germinal center (GC) formation, autoantibody production and disease severity in human systemic lupus erythematosus (SLE).…
Abstract Number: 2215 • 2013 ACR/ARHP Annual Meeting
Apoptotic Cell-Based Therapy To Treat Collagen-Induced Experimental Arthritis. Rationale For The Use Of Apoptotic Cells In The Treatment Of Rheumatoid Arthritis
Sylvain Perruche¹, Amandine Clauzon¹, Francis Bonnefoy¹, Eric Toussirot² and Philippe Saas³, ¹UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, ²Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ³Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France
Background/Purpose: Most of the currently available biological agents used in the treatment of rheumatoid arthritis (RA) target a cellular or soluble factor involved in the…
Abstract Number: 1643 • 2013 ACR/ARHP Annual Meeting
Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg
Gali Malul¹, David Soler², Donald D. Anthony³, Hillard M. Lazarus⁴, Nicholas Lehman⁵, Thomas McCormick², Julia M. Sugalski⁶, Anthony E. Ting⁵ and Nora G. Singer⁷, ¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²Dermatology, Case Medical Center, Cleveland, OH, ³Medicine, Case Western Reserve University, Cleveland, OH, ⁴Comprehensive Cancer Center, Case Medical Center, Cleveland, OH, ⁵Athersys, Inc., Cleveland, OH, ⁶Medicine/infectious disease, Case Western Reserve University, Cleveland, OH, ⁷Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Use of mesenchymal/multipotent stem cells (MSCs/MAPCs) is an emerging immune modulatory therapeutic strategy promising for a number of human diseases. Multipotent adult progenitor cells…
Abstract Number: 1641 • 2013 ACR/ARHP Annual Meeting
Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B
Stefanie Koristka¹, Marc Cartellieri², Claudia Arndt², Anja Feldmann², Irene Michalk², Claudia C. Bippes², Nicole Berndt², Anne Hermsdorf², Slava Stamova², Biji T. Kurien³, Robert Hal Scofield⁴, A. Darise Farris⁵, Judith A. James⁶, Holger Bartsch⁷ and Michael Bachmann², ¹Carl Gustav Carus TU-Dresden, Dresden, Germany, ²Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany
Background/Purpose: Adoptive transfer of regulatory T cells (Tregs) represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…
Abstract Number: 1412 • 2013 ACR/ARHP Annual Meeting
Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Eva Dokoupilova¹, Slawomir Jeka², Jiri Vencovsky³, Janusz Badurski⁴, Klaas Prins⁵, Vibeke Strand⁶, Edward C. Keystone⁷, Ronald F van Vollenhoven⁸, Jurgen Wollenhaupt⁹, Andrea Wartenberg-Demand¹⁰, Gabriele Niemann¹⁰, Ahmed Abufarag¹⁰, Silke Aigner¹⁰, Sibylle Kaiser¹⁰, Faiza Rharbaoui¹⁰, Niklas Czeloth¹¹, Ralf Wolter¹⁰, Benjamin Dälken¹⁰ and Thorsten Holzkämper¹⁰, ¹Medical Plus s.r.o, Uherske Hradiste, Czech Republic, ²Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, ⁵qPharmetra, Nijmegen, Netherlands, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁰Biotest AG, Dreieich, Germany, ¹¹Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: In patients with rheumatoid arthritis (RA) reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed. Tregalizumab is a humanized, agonistic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].